An update on belimumab for the treatment of lupus

References

• MerrillJTClinical trials for lupus – are we there yet?Bull NYU Hosp Jt Dis200967326727019852748
   PubMedGoogle Scholar
• MerrillJTWhat was wrong and might now go right with clinical trials for lupus?Curr Rheumatol Rep200911423523719691925
   PubMedGoogle Scholar
• MerrillJTBuyonJPRituximab: wanted dead or alive …Arthritis Rheum20106282188219120506315
   PubMed Web of Science ®Google Scholar
• BakerKPEdwardsBMMainSHGeneration and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorArthritis Rheum200348113253326514613291
   PubMed Web of Science ®Google Scholar
• DörnerTJacobiAMLeeJLipskyPEAbnormalities of B cell subsets in patients with systemic lupus erythematosusJ Immunol Methods2011363218719720598709
   PubMed Web of Science ®Google Scholar
• FairhurstAMWandstratAEWakelandEKSystemic lupus erythematosus: multiple immunological phenotypes in a complex genetic diseaseAdv Immunol20069216917145301
   PubMed Web of Science ®Google Scholar
• RamanujamMDavidsonABAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?Immunol Rev200822315617418613835
   PubMed Web of Science ®Google Scholar
• TremlJFHaoYStadanlickJECancroMPThe BLyS family: toward a molecular understanding of B cell homeostasisCell Biochem Biophys200953111619034695
   PubMed Web of Science ®Google Scholar
• MackayFSchneiderPCracking the BAFF codeNat Rev Immunol20099749150219521398
   PubMed Web of Science ®Google Scholar
• KhareSDSarosiIXiaXZSevere B cell hyperplasia and autoimmune disease in TALL-1 transgenic miceProc Natl Acad Sci U S A20009773370337510716715
   PubMed Web of Science ®Google Scholar
• RamanujamMWangXHuangWSimilarities and differences between selective and nonselective BAFF blockade in murine SLEJ Clin Invest2006116372473416485042
   PubMed Web of Science ®Google Scholar
• KahnPRamanujamMBethunaickanRPrevention of murine antiphospholipid syndrome by BAFF blockadeArthritis Rheum20085892824283418759321
   PubMed Web of Science ®Google Scholar
• RamanujamMBethunaickanRHuangWTaoHMadaioMPDavidsonASelective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 miceArthritis Rheum20106251457146820131293
   PubMed Web of Science ®Google Scholar
• StohlWJacobNGuoSMorelLConstitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunityArthritis Rheum20106282432244220506216
   PubMed Web of Science ®Google Scholar
• HalpernWGLappinPZanardiTChronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effectsToxicol Sci200691258659916517838
   PubMed Web of Science ®Google Scholar
• CheemaGSRoschkeVHilbertDMStohlWElevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseasesArthritis Rheum20014461313131911407690
   PubMed Web of Science ®Google Scholar
• StohlWMetyasSTanSMB lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsArthritis Rheum200348123475348614673998
   PubMed Web of Science ®Google Scholar
• PetriMStohlWChathamWAssociation of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis Rheum20085882453245918668552
   PubMed Web of Science ®Google Scholar
• CollinsCEGavinALMigoneTSHilbertDMNemazeeDStohlWB lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levelsArthritis Res Ther200681R616356193
   PubMed Web of Science ®Google Scholar
• FurieRStohlWGinzlerEMBiologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusArthritis Res Ther2008105R10918786258
   PubMed Web of Science ®Google Scholar
• WallaceDJStohlWFurieRAA phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Rheum20096191168117819714604
   PubMed Web of Science ®Google Scholar
• PetriMWallaceDJStohlWSLE patients with active production of anti-nuclear autoantibodies (ANA) have distinct patterns of lupus activity and peripheral B-cell biomarkers compared to ANA negative patientsAnn Rheum Dis200665Suppl 2356
   Google Scholar
• FurieRAPetriMAWallaceDJNovel evidence-based systemic lupus erythematosus responder indexArthritis Rheum20096191143115119714615
   PubMed Web of Science ®Google Scholar
• GriffithsBMoscaMGordonCAssessment of patients with systemic lupus erythematosus and the use of lupus disease activity indicesBest Pract Res Clin Rheumatol200519568570816150398
   PubMed Web of Science ®Google Scholar
• Guidance for Industry: Systemic Lupus Erythematosus – Developing Medical Products for TreatmentFood and Drug Administration2006 Available from: http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/Guidances/ucm072063.pdf. Accessed November 10, 2010.
   Google Scholar
• BENLYSTA® (belimumab). Human Genome Sciences. Available from: http://www.hgsi.com/belimumab.html. Accessed November 10, 2010.
   Google Scholar
• Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE). NCT00424476 Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00424476?term=belimumab&cond=systemic+lupus+erythematosus&rank=1. Accessed November 10, 2010.
   Google Scholar
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE). NCT00410384 Available from: http://www.clinicaltrials.gov/ct2/show/NCT00410384?term=belimumab&cond=systemic+lupus+erythematosus&rank=2. Accessed November 10, 2010.
   Google Scholar
• ManziSSanchez-GuerreroJMerrillJTBelimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studiesArthritis Rheum201062Suppl 10607
   Google Scholar
• TanasescuCGallacherAGarciaMBelimumab, a BLyS-specific inhibitor, significantly improved physical functioning, fatigue, and other health-related quality of life (HRQOL) measures in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 studyAnn Rheum Dis201069Suppl 355619723618
   PubMed Web of Science ®Google Scholar
• NavarraSIlianovaEBaeSCBelimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 studyAnn Rheum Dis201069Suppl 3555
   Google Scholar
• Van VollenhovenRZamaniOWallaceDJBelimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 studyAnn Rheum Dis201069Suppl 374
   Google Scholar
• PetriMLevyRAMerrillJTBelimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studiesArthritis Rheum201062Suppl 10190
   Google Scholar
• FurieRAZamaniOWallaceDJBelimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through Wk 76Arthritis Rheum201062Suppl 10606
   Google Scholar
• GuilleminFPrimer: the fallacy of subgroup analysisNat Clin Pract Rheumatol20073740741317599075
   PubMedGoogle Scholar
• BertsiasGKIoannidisJPBoletisJEULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpointsAnn Rheum Dis200968447748318434449
   PubMed Web of Science ®Google Scholar
• KianiANPetriMQuality-of-life measurements versus disease activity in systemic lupus erythematosusCurr Rheumatol Rep201012425025820586000
   PubMedGoogle Scholar
• StrandVLevyRACerveraRBelimumab, a BLyS-specific inhibitor, improved fatigue and SF-36 physical and mental component summary scores in patients with SLE: BLISS-76 and -52 studiesArthritis Rheum201062Suppl 10773
   Google Scholar
• LevyRAIlianovaEIonescuRBelimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies and normalized low complement in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 studyAnn Rheum Dis201069Suppl 355619723618
   PubMed Web of Science ®Google Scholar
• StohlWHiepeFThomasMBelimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies, normalized low complement, and reduced selected B-cell populations in patients with seropositive systemic lupus erythematosus (SLE): the phase 3 BLISS studiesArthritis Rheum201062Suppl 10480
   Google Scholar
• ChathamWWallaceDJStohlWEffect of belimumab, a B-lymphocyte stimulator-specific inhibitor, on functional antibodies to pneumococcal, tetanus, and influenza vaccinesArthritis Rheum201062Suppl 10192
   Google Scholar
• ChathamWWeinsteinAPetriMFive-year safety and efficacy experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE)Ann Rheum Dis201069Suppl 3147
   Google Scholar
• MerrillJTWallaceDJFurieRAFive-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE)Arthritis Rheum201062Suppl 10608
   Google Scholar
• GinzlerEMWallaceDJChathamWBelimumab (fully human monoclonal antibody to BLyS) reduced steroid use in systemic lupus erythematosus (SLE) patients during 3 years of therapyAnn Rheum Dis200867Suppl 2217
   Google Scholar
• ChathamWAranowCFurieRProgressive normalization of autoantibody, immunoglobulin, and complement levels over 3 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus (SLE) patientsAnn Rheum Dis200867Suppl 2217
   Google Scholar
• JacobiAMHuangWWangTEffect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging studyArthritis Rheum201062120121020039404
   PubMed Web of Science ®Google Scholar
• A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States. NCT00724867 Available from: http://www.clinicaltrials.gov/ct2/show/NCT00724867?term=belimumab&rank=9. Accessed November 10, 2010.
   Google Scholar
• A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™) a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057. NCT00712933 Available from: http://www.clinicaltrials.gov/ct2/show/NCT00712933?term=belimumab&rank=11. Accessed November 10, 2010.
   Google Scholar
• A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE). NCT00732940 Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00732940?term=belimumab&cond=systemic+lupus+erythematosus&rank=3. Accessed November 10, 2010.
   Google Scholar